ORPHA:873
Desmoid tumor
Also known as: Aggressive fibromatosis · Desmoid type fibromatosis
Publications
7,493
Trials
35
Interventional, condition-specific
Researchers
1,177
Distinct authors in sample
Gene link
APC
Definitive
Readiness
5/6
Stages with a signal
Clinical definition (Orphanet)
A desmoid tumor (DT) is a benign, locally invasive soft tissue tumor associated with a high recurrence rate but with no metastatic potential.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007608
- MeSH:D018222
- OMIM:135290
- UMLS:C0079218
- NCIT:C9182
Additional Mondo synonyms (8)
aggressive fibromatosis · deep fibromatosis · deep fibromatosis/desmoid tumor · deep fibromatosis/desmoid tumour · desmoid fibromatosis · desmoid tumor · desmoid type fibromatosis · desmoid-type fibromatosis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — APC
- LiteraturePresent
7,493 matched papers (3,926 in last 10 years) Source
- Phenotype characterisedPresent
24 HPO annotations (e.g. Intestinal obstruction; Abnormal retinal pigmentation; Gastrointestinal desmoid tumor) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationPresent
4 FDA designations (4 FDA orphan-indication approvals) — e.g. sorafenib Source
- Interventional trialPresent
35 matched on ClinicalTrials.gov (7 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (APC).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
24
Associated phenotypes · MONDO:0007608
- Intestinal obstruction
- Abnormal retinal pigmentation
- Gastrointestinal desmoid tumor
- Chest pain
- Hydronephrosis
Showing 5 of 24 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
4
Designations · 4 with FDA orphan-indication approval
- FDA sorafenibdesmoid tumors · 2019-02-28 · Not FDA Approved for Orphan Indication
- FDA nirogacestatDesmoid tumor · 2018-06-07 · Not FDA Approved for Orphan Indication
- FDA tegavivintdesmoid tumors · 2018-04-11 · Not FDA Approved for Orphan Indication
- FDA Toremifenedesmoid tumors · 1993-08-17 · Not FDA Approved for Orphan Indication
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
32
Drugs / clinical candidates · MONDO_0007608
- DOXORUBICIN·phase 3
- SORAFENIB TOSYLATE·phase 3
- AMINOLEVULINIC ACID·phase 2
- AMINOLEVULINIC ACID HYDROCHLORIDE·phase 2
- HYDROXYUREA·phase 2
- IMATINIB·phase 2
- METHOTREXATE·phase 2
- NIVOLUMAB·phase 2
- PACLITAXEL·phase 2
- PAZOPANIB·phase 2
- SULINDAC·phase 2
- TALIMOGENE LAHERPAREPVEC·phase 2
- TAMOXIFEN·phase 2
- TOREMIFENE·phase 2
- TRABECTEDIN·phase 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
7,493
7,493 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
7,493 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
3,926 in the last 10 years · low confidence
Phrase hits: 7,493 · MeSH hits: 0
Who's working on it?
1,177
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Colombo C6 papers · 2026
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Papers in Europe PMC - 02Fiore M6 papers · 2026
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Papers in Europe PMC - 03Gronchi A6 papers · 2026
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Papers in Europe PMC - 04Wang X5 papers · 2026
Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Papers in Europe PMC - 05Wang Y5 papers · 2026
Division of Gastrointestinal Surgery, Department of General Surgery, West China Hospital, Sichuan University, No 37, Guo Xue Xiang St, Chengdu, 610041, China.
Papers in Europe PMC - 06Bonvalot S4 papers · 2026
Department of Surgical Oncology, Institut Curie, 26 rue d'Ulm, Paris 75005, France. Electronic address: sylvie.bonvalot@curie.fr.
Papers in Europe PMC - 07Kasper B4 papers · 2026
Sarcoma Unit, University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center (MCC), Theodor-Kutzer-Ufer 1-3, Mannheim D-68167, Germany.
Papers in Europe PMC - 08Baumgarten C3 papers · 2026
SOS-Desmoid, e.V., SPAEN Sarcoma Patients EuroNet e.V, 61200 Wölfersheim, Germany.
Papers in Europe PMC - 09Eichler M3 papers · 2026
National Center for Tumor Diseases (NCT/UCC) Dresden, Medical Faculty, Technical University Dresden, 01307 Dresden, Germany.
Papers in Europe PMC - 10Hoffmann R3 papers · 2026
National Center for Tumor Diseases (NCT/UCC) Dresden, Medical Faculty, Technical University Dresden, 01307 Dresden, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
35
interventional trials for this specific condition
35 interventional trials matched this specific condition name; 7 currently recruiting in our sample.
Data as of 11 September 2026
35 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 96.3th percentile).
low confidence · 96.3th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
35 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04851119·RECRUITING·Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Not reviewed·Conditions: Colorectal Carcinoma · Endometrial Carcinoma · Melanoma · Neuroblastoma·Matched via name phrase
- NCT07176689·RECRUITING·Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Not reviewed·Conditions: Desmoid Tumor · Aggressive Fibromatosis·Matched via name phrase
- NCT05500391·RECRUITING·Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Not reviewed·Conditions: Stage I Testicular Seminoma · Stage I Testicular Nonseminomatous Germ Cell Tumor · Gastrointestinal Stromal Tumors · Ovarian Germ Cell Tumor·Matched via name phrase
- NCT06081400·RECRUITING·Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting
Not reviewed·Conditions: Desmoid Tumor·Matched via name phrase
- NCT06355921·NOT YET RECRUITING·A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors
Not reviewed·Conditions: Desmoid Tumor · Desmoid Fibromatosis · Desmoid·Matched via name phrase
- NCT05949099·RECRUITING·Study of Cryoablation and Nirogacestat for Desmoid Tumor
Not reviewed·Conditions: Desmoid Tumor·Matched via name phrase
- NCT07541430·RECRUITING·A Study in Adults With Desmoid Tumors
Not reviewed·Conditions: Desmoid Tumor·Matched via name phrase
Observational and natural-history studies
17 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06945887·RECRUITING·Treatment of Desmoid Fibromatosis With Arterial Embolization
Not reviewed·Conditions: Desmoid Fibromatosis·Matched via name phrase
- NCT06268457·RECRUITING·Arterial Chemoembolization for the Treatment of Desmoid Fibromatosis
Not reviewed·Conditions: Desmoid·Matched via name phrase
- NCT06224283·RECRUITING·Radiomics Compared With Conventional Response Criteria for Predicting Progression of Desmoid Tumor After Cryoablation
Not reviewed·Conditions: Desmoid·Matched via name phrase
- NCT02402244·RECRUITING·Project: Every Child for Younger Patients With Cancer
Not reviewed·Conditions: Adrenal Gland Pheochromocytoma · Carcinoma In Situ · Central Nervous System Neoplasm · Childhood Immature Teratoma·Matched via name phrase
- NCT07496242·RECRUITING·Immunological Phenotype of Desmoid-fibromatosis-affected Patients.
Not reviewed·Conditions: Desmoid-Type Fibromatosis·Matched via name phrase
- NCT04281381·RECRUITING·Observing People With Desmoid-Type Fibromatosis
Not reviewed·Conditions: Desmoid Fibromatosis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 5 · after dedupe 5 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 5 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (5)
- isrctn·ISRCTN17721852·No longer recruiting·Retrospective study in patient with soft tissue sarcoma of trunk wall and extremities who have been treated with surgery in association or not with chemotherapy and/or radiotherapy, to point out the response to preoperative treatment and outcome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76456502·No longer recruiting·Radiotherapy given to a reduced area following surgery in adult patients with limb, hand or foot soft tissue sarcoma to find out if it will cause fewer side effects, without increasing the risk of the sarcoma coming back
skipped — LLM skipped (--skip-llm)
- ctis·2025-521402-18-00·Cancelled·Phase 1 Study to Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Men Participants
skipped — LLM skipped (--skip-llm)
- ctis·2024-515215-21-00·Authorised, ongoing·A Single-arm, Open-label Phase 4 Study of Nirogacestat in Adult Premenopausal Females with Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
skipped — LLM skipped (--skip-llm)
- ctis·2024-517185-42-00·Revoked·Phase 1 study of a Propranolol (HEMANGIOL®) and oral metronomic Vinorelbine (NAVELBINE®) combination on children and teenagers With Refractory/Relapsing Solid Tumors - PROVIN
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Desmoid tumor — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Desmoid tumor" OR "Aggressive fibromatosis" OR "Desmoid type fibromatosis" OR "deep fibromatosis" OR "deep fibromatosis/desmoid tumor" OR "deep fibromatosis/desmoid tumour" OR "desmoid fibromatosis" OR "desmoid-type fibromatosis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Desmoid tumor" OR "Aggressive fibromatosis" OR "Desmoid type fibromatosis" OR "deep fibromatosis" OR "deep fibromatosis/desmoid tumor" OR "deep fibromatosis/desmoid tumour" OR "desmoid fibromatosis" OR "desmoid-type fibromatosis"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 35 interventional · 17 observational · 2 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (7493) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T15:42:55.894Z
